![](https://investorshub.advfn.com/uicon/276021.png?cb=1471598439)
Monday, December 05, 2011 9:32:35 AM
VistaGen, a biotechnology company applying human pluripotent stem cell technology to drug rescue and cell therapy, is able to take advantage of a science advisory board with a wealth of experience in dealing with the pharmaceutical industry. It’s a critical asset as the company introduces its revolutionary approach for early drug candidate safety testing, potentially saving major drug companies millions or even billions of dollars over traditional approaches. With an intimate knowledge of the commercial criteria driving Big Pharma, the board is able to apply both scientific expertise and commercial insight into the challenges and opportunities involved in bringing new drugs to the marketplace.
• Gordon Keller, Ph.D., was recently named a “Top 25 Transformational Canadian” for his stem cell research. He’s Director of UHN’s McEwen Centre, and Professor at the Department of Medical Biophysics, University of Toronto, Ontario. He is considered a world leader in the field of hematopoietic development with more than 100 publications relating to blood development and stem cells.
• Peter Backx, Ph.D., D.V.M., has more than 200 publications in electrophysiology, ion channels biochemistry, and heart disease. He has served on several NIH grant study sections, is a reviewer for 69 multiple scientific journals, and has been a past Chair of multiple committees for the Heart & Stroke Foundation of Canada.
• George Clay, Ph.D., is the retired COO of Kyowa Pharmaceuticals, and has 13 years of experience in the worldwide registration of drugs and biologics. He also has many years in preclinical research in neuronal and gastroenterology, as well as drug development and regulatory affairs.
• Arthur Fetter, Ph.D., D.V.M., is the retired Sr. VP of Worldwide Drug Safety for Rhone-Poulenc Rorer, and has over 20 years of veterinary pathology/toxicology and senior management experience in preclinical safety assessment of pharmaceuticals and medical devices.
• Jack Gauldie, Ph.D., is Director at the Centre for Gene Therapeutics, McMaster University, and is recognized internationally for his work in defining the molecular regulation of the acute phase inflammatory response. He is considered a world expert in cytokine biology and the molecular regulation of inflammation and immunity.
• John Lowe, Ph.D., is a retired Sr. Research Fellow of Medicinal Chemistry and Drug Discovery for Pfizer Global R&D, and has authored 88 publications in chemistry, pharmacology, and drug design. He is the inventor or co-inventor on over 60 patents.
• James Sanders, Ph.D., D.V.M., is the retired Sr. Director and Preclinical Development Leader for Johnson & Johnson, and has over 30 years of experience in toxicology, safety assessment, drug development and regulatory affairs in senior global positions at world-leading pharmaceutical companies.
• Ron Wester, Ph.D., is the retired VP of Medicinal Chemistry and Drug Discovery for Pfizer Global R&D, and has nearly 25 years of experience in medicinal chemistry and drug development, with strategic leadership responsibilities for drug discovery technologies across chemistry, biology and computational disciplines.
Recent VTGN News
- Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine • Business Wire • 07/09/2024 12:30:00 PM
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM